Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies
Acrodermatitis continua of Hallopeau (ACH) is a rare aseptic pustular dermatosis for which clinical guidelines are lacking and treatment is largely based on case reports. Biologically targeted therapies offer new therapeutic ideas, with TNF antagonists such as adalimumab showing promising efficacy i...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1525821/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849762376307441664 |
|---|---|
| author | Qiong Sun Luyao Han Zhimin Lin Yuanhao Wu Chen Li Zhenhua Ying Zhenhua Ying Zhenhua Ying Zuotao Zhao |
| author_facet | Qiong Sun Luyao Han Zhimin Lin Yuanhao Wu Chen Li Zhenhua Ying Zhenhua Ying Zhenhua Ying Zuotao Zhao |
| author_sort | Qiong Sun |
| collection | DOAJ |
| description | Acrodermatitis continua of Hallopeau (ACH) is a rare aseptic pustular dermatosis for which clinical guidelines are lacking and treatment is largely based on case reports. Biologically targeted therapies offer new therapeutic ideas, with TNF antagonists such as adalimumab showing promising efficacy in both adults and children.The IL-17 and IL-23 axes play a key role in the pathogenesis of ACH, and anti-IL-17A and anti-IL-23 antibodies have shown therapeutic efficacy. In addition, new therapies such as IL-36 inhibitors and JAK inhibitors are being explored. Although biologics provide a new direction for ACH treatment, their safety and efficacy still need to be confirmed by large-scale clinical studies. |
| format | Article |
| id | doaj-art-0e8406bfd0c246f6a32a67ec98adfc25 |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-0e8406bfd0c246f6a32a67ec98adfc252025-08-20T03:05:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.15258211525821Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapiesQiong Sun0Luyao Han1Zhimin Lin2Yuanhao Wu3Chen Li4Zhenhua Ying5Zhenhua Ying6Zhenhua Ying7Zuotao Zhao8Department of Rheumatology and Immunology, Affiliated Hospital of Shaoxing University (Shaoxing Municipal Hospital), Zhejiang, ChinaFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, ChinaCapital Medical University Beijing Hospital of Traditional Chinese Medicine, Beijing, ChinaFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, ChinaDepartment of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, ChinaDepartment of Rheumatology and Immunology, Center for General Practice Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Zhejiang, ChinaInstitute of Rheumatology and Immunology, Hangzhou Medical College, Zhejiang, ChinaZhejiang Provincial Key Laboratory of Traditional Chinese Medicine Cultivation for Arthritis Diagnosis and Treatment, Zhejiang, ChinaDepartment of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, ChinaAcrodermatitis continua of Hallopeau (ACH) is a rare aseptic pustular dermatosis for which clinical guidelines are lacking and treatment is largely based on case reports. Biologically targeted therapies offer new therapeutic ideas, with TNF antagonists such as adalimumab showing promising efficacy in both adults and children.The IL-17 and IL-23 axes play a key role in the pathogenesis of ACH, and anti-IL-17A and anti-IL-23 antibodies have shown therapeutic efficacy. In addition, new therapies such as IL-36 inhibitors and JAK inhibitors are being explored. Although biologics provide a new direction for ACH treatment, their safety and efficacy still need to be confirmed by large-scale clinical studies.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1525821/fullAcrodermatitis continua of Hallopeauimmune targeted therapyTNF inhibitorIL-17 inhibitorJAK inhibitor |
| spellingShingle | Qiong Sun Luyao Han Zhimin Lin Yuanhao Wu Chen Li Zhenhua Ying Zhenhua Ying Zhenhua Ying Zuotao Zhao Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies Frontiers in Immunology Acrodermatitis continua of Hallopeau immune targeted therapy TNF inhibitor IL-17 inhibitor JAK inhibitor |
| title | Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies |
| title_full | Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies |
| title_fullStr | Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies |
| title_full_unstemmed | Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies |
| title_short | Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies |
| title_sort | acrodermatitis continua of hallopeau a review and update on biological and small molecule targeted immunomodulatory therapies |
| topic | Acrodermatitis continua of Hallopeau immune targeted therapy TNF inhibitor IL-17 inhibitor JAK inhibitor |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1525821/full |
| work_keys_str_mv | AT qiongsun acrodermatitiscontinuaofhallopeauareviewandupdateonbiologicalandsmallmoleculetargetedimmunomodulatorytherapies AT luyaohan acrodermatitiscontinuaofhallopeauareviewandupdateonbiologicalandsmallmoleculetargetedimmunomodulatorytherapies AT zhiminlin acrodermatitiscontinuaofhallopeauareviewandupdateonbiologicalandsmallmoleculetargetedimmunomodulatorytherapies AT yuanhaowu acrodermatitiscontinuaofhallopeauareviewandupdateonbiologicalandsmallmoleculetargetedimmunomodulatorytherapies AT chenli acrodermatitiscontinuaofhallopeauareviewandupdateonbiologicalandsmallmoleculetargetedimmunomodulatorytherapies AT zhenhuaying acrodermatitiscontinuaofhallopeauareviewandupdateonbiologicalandsmallmoleculetargetedimmunomodulatorytherapies AT zhenhuaying acrodermatitiscontinuaofhallopeauareviewandupdateonbiologicalandsmallmoleculetargetedimmunomodulatorytherapies AT zhenhuaying acrodermatitiscontinuaofhallopeauareviewandupdateonbiologicalandsmallmoleculetargetedimmunomodulatorytherapies AT zuotaozhao acrodermatitiscontinuaofhallopeauareviewandupdateonbiologicalandsmallmoleculetargetedimmunomodulatorytherapies |